Clinical Practice Guidelines for the management of locally advanced ...

76. Little DJ, Kuban DA, Levy LB, Zagars GK, Pollack A. Quality-of-life questionnaire results 2
and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study.
Urology 62(4):707-13, 2003.
77. Kuban DA, Tucker SL, Dong L et al. Long-term results of the M. D. Anderson randomized
dose-escalation trial for prostate cancer. International Journal of Radiation Oncology, Biology,
Physics 2008;70(1):67-74.
78. Beckendorf V, Guerif S, Le Prise E et al. The GETUG 70 Gy vs. 80 Gy randomized trial for
localized prostate cancer: feasibility and acute toxicity. International Journal of Radiation
Oncology, Biology, Physics 60(4):1056-65, 2004.
79. Koper PC, Stroom JC, van Putten WL et al. Acute morbidity reduction using 3DCRT for
prostate carcinoma: a randomized study. International Journal of Radiation Oncology, Biology,
Physics 43(4):727-34, 1999.
80. Koper PC, Jansen P, van Putten W et al. Gastro-intestinal and genito-urinary morbidity after 3D
conformal radiotherapy of prostate cancer: observations of a randomized trial. Radiotherapy &
Oncology 73(1):1-9, 2004.
81. Dearnaley DP, Khoo VS, Norman AR et al. Comparison of radiation side-effects of conformal
and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 353(9149):267-72,
1999.
82. Kuban D, Pollack A, Huang E et al. Hazards of dose escalation in prostate cancer radiotherapy.
International Journal of Radiation Oncology, Biology, Physics 57(5):1260-8, 2003.
83. Paulson DF, Hodge GB, Jr., Hinshaw W. Radiation therapy versus delayed androgen
deprivation for stage C carcinoma of the prostate. Journal of Urology 131(5):901-2, 1984.
84. Akakura K, Isaka S, Akimoto S et al. Long-term results of a randomized trial for the treatment
of Stages B2 and C prostate cancer: radical prostatectomy versus external beam radiation
therapy with a common endocrine therapy in both modalities. Urology 1999;54(2):313-318.
85. Akakura K, Suzuki H, Ichikawa T et al. A randomized trial comparing radical prostatectomy
plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally
advanced prostate cancer: results at median follow-up of 102 months. Jpn J Clin Oncol
2006;36(12):789-793.
86. Isaka S, Shimazaki J, Akimoto S et al. A prospective randomized trial for treating stages B2
and C prostate cancer: radical surgery or irradiation with neoadjuvant endocrine therapy. Jpn J
Clin Oncol 1994;24(4):218-223.
87. Widmark A, Klepp O, Solberg A et al. Endocrine treatment, with or without radiotherapy, in
locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet
2009;373(9660):301-308.
88. Sathya JR, Davis IR, Julian JA et al. Randomized trial comparing iridium implant plus
external-beam radiation therapy with external-beam radiation therapy alone in node-negative
locally advanced cancer of the prostate. Journal of Clinical Oncology 2005;23(6):1192-1199.
89. Horwitz EM, Winter K, Hanks GE, Lawton CA, Russell AH, Machtay M. Subset analysis of
RTOG 85-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones
for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy.
International Journal of Radiation Oncology, Biology, Physics 49(4):947-56, 2001.
90. Zagars GK, Johnson DE, Von Eschenbach AC, Hussey DH. Adjuvant estrogen following
radiation therapy for stage C adenocarcinoma of the prostate: long-term results of a prospective
randomized study. International Journal of Radiation Oncology, Biology, Physics 14(6):1085-
91, 1988.
45
Locally advanced disease